Genetics Flashcards
(126 cards)
autosomal dominant inheritance
· More than one generation involved
· Male to male transmission
· Males and females affected with equal severity
· Penetrance: affected person showing clinical symptoms
· Expressivity: variation in clinical presentation
autosomal recessive inheritance
One or more affected children with unaffected parents
Usually only one generation involved
Males and females affected with equal frequency and severity
A higher incidence of consanguinity
X-linked inheritance
Usually only males affected
More than one generation involved with the disease appearing to be passed on through normal females
No male to male transmission
X inactivation
Carrier females affected by X-linked disorders as a consequence of X-inactivation/lyonization -> random, normal X chromosome switched off in excess of cells leaving diseased X= manifestation of disease
Fragile X Syndrome
commonest non chromosome cause of mental retardation
- 1:4000
Symptoms:
- Mild-severe mental retardation
- Macroorchidism (post pubertal)- abnormally large testes
- Long face, prominent jaw, thick nasal bridge, large ears
- Joint hypermobility
- Autistic features
Consanguity of first, second and third degree relatives
first= 50% (100% if identical) second= 25% third= 12.5%
Fetal Sex on Maternal Blood- cell free fetal DNA (cffDNA)
- Originates from placental trophoblast & shed into maternal blood stream, detectable from 4-5w gestation (increases with progression)- Can be analysed to detect Y specific sequence of male
- 3-6% of total DNA in maternal plasma, cleared rapidly post delivery
- Used for early non-invasive prenatal determination of sex for foetuses at risk of X linked disorders (avoid invasive CVS for female foetus)
Chorionic Villus Sampling- invasive
- Piece of placenta -> DNA extraction and chromosome analysis
- performed 11w gestation, miscarriage risk= 1.5-2%
- PCR based test (DNA extracted without culture), result in three days
Amniocentesis
- Removal of 10-20ml amniotic fluid under ultrasound control, contain cells from baby and placental membranes: chromosome analysis and DNA molecular analysis
- Performed 15w gestation onwards, miscarriage risk= 0.5-1%
Amnio-PCR
- Amplification of polymorphic markers on chromosomes 21, 18 and 13 based on limited PCR cycles= quantification of results
Preimplantation Genetic Diagnosis
IVF creation of embryo from egg and sperm of couple, each embryo tested for particular genetic disorder and one unaffected embryo is transferred into womb -> pregnancy
- for couples at risk of having a child with a single deep gene disorder or chromosomal disorder
Criteria for PGD (NHS funded)
known genetic condition, female age >39, no unaffected living child, female BMI< 30, non-smoker, AMH>/= 6, antral follicle count >8
Haemoglobinopathies Antenatal Screening Programme
- Screening for sickle cell anaemia and other haemoglobin variants based on Family Origin Questionnaire to assess risk, women and/or partners in high risk groups
- Screening for thalassemia based on inspection of routine blood indices
Screening for Trisomy 21, Trisomy 18 & Neural Tube Defects
- First trimester screening (nuchal transparency, HCG, PAPP-A) offered 11-14w
- Second trimester screening (missed first) offered 15-20w, measure AFP, HCG, unconjugated oestridiol & inhibin A
High HCG: AFP ratio increases
chances for Down Syndrome
AFP<2 multiples of median adjusted for maternal wight indicates
increased risk of neural tube defect, 90% identified in second trimester detailed screening
When is ultrasound screening for fetal anomaly carried out in low risk women?
Ultrasound screening for fetal anomaly in low risk women performed 18-20w gestation
endophenotypes
if 1 person in family has disease, other people in family may have it with low expressivity eg. on the spectrum
How do you know if a disease is genetically determined?
- Segregation analysis– this looks for patterns in the family history of affected individuals
- Using twin studies which compare the concordance of disease between monozygous (identical) twins to the concordance of the same disease in dizygous (fraternal) twins
Both of these techniques provide a quantitative measure of how “genetic” a disease is. Diagnostic genetic testing is currently only available in mendelian disease.
Newborn Screening in Scotland
- phenylketonuria (PKU)
- congenital hypothyroidism (CHT)
- cystic fibrosis (CF)
- medium chain acyl-CoA dehydrogenase deficiency (MCADD)
- sickle cell disorder (SCD)
- hearing loss
Phenylketonuria (PKU)
- 1/6000 in Scotland
- clinically silent in first months
- eczema, hypopigmentation, severe developmental delay by toddler age, ‘mousy’ smell to urine (from build-up of intermediate phenyl-acetate)
- all babies have testing at 7 days
what mutation leads to PKU?
mutation in both copies of PAH gene- no phenylalanine hydroxylase activity > build-up of phenylalanine (neurotoxin) leading to intellectual disability
Treatment for PKU
phenylalanine-restricted diet started <21 days, continue diet for life and leads to normal outcome in most children
Criteria for population based screening:
- Well defined disorder
- Known incidence
- Significant morbidity or mortality
- Effective treatment available
- Period before onset during which intervention improves outcome
- Ethical, safe, simple and robust screening test
- Cost effective